Skip to main content
eScholarship
Open Access Publications from the University of California

Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.

  • Author(s): Bahmani, Baharak
  • Uehara, Mayuko
  • Ordikhani, Farideh
  • Li, Xiaofei
  • Jiang, Liwei
  • Banouni, Naima
  • Ichimura, Takaharu
  • Kasinath, Vivek
  • Eskandari, Siawosh K
  • Annabi, Nasim
  • Bromberg, Jonathan S
  • Shultz, Leonard D
  • Greiner, Dale L
  • Abdi, Reza
  • et al.
Abstract

BACKGROUND:Nanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by enhancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in lymph nodes or formed de novo in peripheral tissues during inflammatory responses. They express peripheral node addressin (PNAd), which is recognized by the monoclonal antibody MECA79. METHODS:Here, we demonstrated that HEVs form de novo in human pancreatic ductal adenocarcinoma (PDAC). We engineered MECA79 coated nanoparticles (MECA79-NPs) that recognize these ectopic HEVs in PDAC. FINDINGS:The trafficking of MECA79-NPs following intravenous delivery to human PDAC implanted in a humanized mouse model was more robust than non-conjugated NPs. Treatment with MECA79-Taxol-NPs augmented the delivery of Paclitaxel (Taxol) to the tumor site and significantly reduced the tumor size. This effect was associated with a higher apoptosis rate of PDAC cells and reduced vascularization within the tumor. INTERPRETATION:Targeting the HEVs of PDAC using MECA79-NPs could lay the ground for the localized delivery of a wide variety of drugs including chemotherapeutic agents. FUND: National Institutes of Health (NIH) grants: T32-EB016652 (B·B.), NIH Cancer Core Grant CA034196 (L.D.S.), National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (R.A.).

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View